当前药理管理在晚期心力衰竭患者中的作用和应用
Alberto Palazzuoli1, Gaetano Ruocco2, Marco Giuseppe Del Buono3
1Cardiovascular Diseases Unit, Cardiothoracic and Vascular Department, Le Scotte Hospital, University of Siena, Viale Bracci 12, 53100, Siena, Italy. palazzuoli2@unisi.it.
Heart failure reviews
|January 29, 2024
概括
晚期心力衰竭 (ADVHF) 患者经常面临药物不耐受和有限的治疗选择. 本综述探讨了个性化方法,以优化ADVHF患者的药物耐受性和生活质量 (QoL).
科学领域:
- 心脏病学 心脏病学
- 心脏衰竭管理的管理
- 药物治疗 药物治疗
背景情况:
- 晚期心力衰竭 (ADVHF) 带来了复杂的挑战,包括药物不耐受和多器官功能障碍.
- 目前的指导方针为ADVHF药疗提供了有限的具体建议,特别是在NYHA Class IV患者的指导方针导向医疗疗 (GDMT) 方面.
- 在ADVHF中对GDMT的现有研究很少,结果相互矛盾,重点是稳定患者.
研究的目的:
- 审查在ADVHF中使用传统心力衰竭药物的常见陷和局限性.
- 为ADVHF患者提供个性化的治疗方法.
- 为了优化药物耐受性,不良事件保护和生活质量 (QoL) 在ADVHF.
主要方法:
- 审查关于ADVHF分类,特征和治疗策略的现有文献.
- 在心力衰竭 (HF) 的晚期阶段对当前GDMT的局限性的分析.
- 综合证据,提出针对ADVHF的个性化药物治疗算法.
主要成果:
- ADVHF的特点是药物不耐受性,低血压,多器官功能障碍和尿剂依赖.
- 在ADVHF和NYHA类IV中,当代GDMT (四种药物类别) 的证据有限.
- 像运动耐受性和QoL这样的硬终点在ADVHF当前的治疗方法中没有得到充分的证明.
结论:
- 在ADVHF中,有必要制定量身定制的治疗策略,以平衡药物耐受性和疗效.
- 个性化方法对于改善ADVHF患者的治疗结果和生活质量至关重要.
- 需要进一步的研究来确定ADVHF的最佳药物选择,剂量和管理.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:22Heart Failure Drugs: β-Blockers
340
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
340
01:26Heart Failure Drugs: Inotropic Agents
588
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
588
01:22Heart Failure Drugs: Diuretics
381
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
381
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
515
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
515